Improve Compliance and Create Transparency with 340B Rebates
Updated: Sep 29, 2020
In a recent post by Adam J. Fein, CEO of Drug Channels Institute, he shares insight on why the 340B Drug Pricing Program needs to become a "more transparent, properly regulated program".
Drug Channels Institute is holding a live video webinar to educate the industry on 340B rebates, with Founder and CEO of Kalderos, Jeremy Docken.
Missed the webinar on September 11th, 2020? No worries!
Click here to access the recording.
